Development of Innovative Foldamers for the Peptide Receptor Radionuclide Therapy of Tumours Overexpressing Cholecystokinin-2 Receptors
Development of Innovative Foldamers for the Peptide Receptor Radionuclide Therapy of Tumours Overexpressing Cholecystokinin-2 Receptors
批准号:
nhmrc : GNT1158863
负责人:
金额:
$61.41万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2019
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2019-01-01 至 --
中文摘要
肽受体放射性核素疗法(PRRT)是一种系统的治疗方法,使用被称为治疗剂(TAs)的放射性药物向癌症提供高水平的辐射。到目前为止,TAs仅限于几种癌症类型。该项目旨在开发TAs来治疗过度表达重要分子靶点胆囊收缩素-2 (CCK-2)受体的癌症。这些TAs将以创新的方式制备,以显示对CCK-2受体的高亲和力和稳定性。
英文摘要
Peptide Receptor Radionuclide Therapy (PRRT) is a systematic treatment used to deliver high levels of radiation to cancer using radiopharmaceuticals known as theranostic agents (TAs). Until now TAs have been limited to only a few cancer types. This project aims to develop TAs to treat cancers which overexpress an important molecular target known as Cholecystokinin-2 (CCK-2) receptors. These TAs will be prepared in an innovative manner to display high affinity and stability for CCK-2 receptors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金